SCHEMBL12098073

SCHEMBL12098073

CC1(C)OB(c2cccnc2OCC2CC2)OC1(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ ROCK2 O75116 1/20 0.34
▸ HTR2C P28335 3/20 0.34
▸ HTR4 Q13639 3/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ HTR3A P46098 2/20 0.34
▸ FFAR4 Q5NUL3 2/20 0.34
▸ ACHE P22303 1/20 0.34
▸ CNR2 P34972 2/20 0.33
▸ CNR1 P21554 1/20 0.33
▸ GRM4 Q14833 2/20 0.33
▸ LIPE Q05469 1/20 0.33
▸ PDE5A O76074 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ GPBAR1 Q8TDU6 1/20 0.32
▸ HTR1A P08908 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31441629 0.95 FFAR4 (0.37) ALOX5APFEN1ROCK2HTR2CHTR4
SCHEMBL365301 0.81 L3MBTL1 (0.36) LIPE
SCHEMBL29900384 0.81 L3MBTL1 (0.36) LIPE
SCHEMBL22040325 0.81 ROCK2 (0.41) ALOX5APFEN1ROCK2LIPE
SCHEMBL29513574 0.81 ROCK2 (0.41) ALOX5APFEN1ROCK2LIPE
SCHEMBL30138169 0.79 LPL (0.36) ROCK2LIPEPDE5APDE4APDE4B
SCHEMBL9998673 0.79 LPL (0.36) ROCK2LIPEPDE5APDE4APDE4B
SCHEMBL986207 0.79 RIPK1 (0.46) HTR2CHTR2BCNR2CNR1PDE5A
SCHEMBL31441507 0.78 ROCK2 (0.40) ALOX5APFEN1ROCK2FFAR4LIPE
SCHEMBL31441748 0.78 ROCK2 (0.40) ALOX5APFEN1ROCK2FFAR4PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11020381-B2 Biaryloxy derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2021-06-01 — — US disclosed
US-20200230123-A1 BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2020-07-23 — — US disclosed
EP-3676248-A1 BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS RaQualia Pharma Inc. (JP) 2020-07-08 — — EP disclosed
CN-111132961-A Bisaryloxy derivatives as TTX-S blockers 拉夸里亚创药株式会社 2020-05-08 — — CN disclosed
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2019-08-20 — — US disclosed
WO-2019045035-A1 BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2019-03-07 — — WO disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 — — EP disclosed
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2015-06-04 — — US disclosed
EP-2681194-B1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN LA ROCHE (CH) 2015-04-15 — — EP disclosed
US-8987307-B2 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. (US) 2015-03-24 — — US disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed
EP-2681194-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2014-01-08 — — EP disclosed
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS HOFFMANN-LA ROCHE INC. 2012-09-13 — — US disclosed
WO-2012117000-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385022-B2 3-amino-pyridines as GPBAR1 agonists GPBAR1, ADRA1B, GPR119 ALOX5AP 1459/4885FEN1 4365/4885ROCK2 3930/4885
US-20120232051-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 ALOX5AP 1459/4885FEN1 4365/4885ROCK2 3930/4885
US-11020381-B2 Biaryloxy derivatives as TTX-S blockers SCN1B, SCN3A, SCN2B ALOX5AP 2117/4885FEN1 4829/4885ROCK2 2368/4885
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 ALOX5AP 3295/4885FEN1 1939/4885ROCK2 1621/4885
US-20150152058-A1 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS GPBAR1, ADRA1B, GPR119 ALOX5AP 1459/4885FEN1 4365/4885ROCK2 3930/4885
US-20200230123-A1 BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN3A, SCN2B ALOX5AP 2117/4885FEN1 4829/4885ROCK2 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback